Expertise in
54
conditions

Dr. Donald Doll

Oncology
Curators Of The University Of Missouri
1 Hospital Dr, 
Columbia, MO 
Expertise in
54
conditions
Curators Of The University Of Missouri
1 Hospital Dr, 
Columbia, MO 

Overview

Donald Doll is an Oncologist in Columbia, Missouri. Dr. Doll is highly rated in 54 conditions, according to our data. His top areas of expertise are Autoimmune Hemolytic Anemia, Astrocytoma, Posterior Fossa Tumor, Gliosarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD

Locations

Curators of the University of Missouri
1 Hospital Dr, Columbia, MO 65212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
View 4 Less Clinical Trials

22 Total Publications

Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
Journal: Oncology (Williston Park, N.Y.)
Published: July 27, 2023
Similar Doctors
Expertise in
87
conditions
Dr. Umasankar Ramadoss
Hematology | Oncology
Expertise in
87
conditions
Dr. Umasankar Ramadoss
Hematology | Oncology

Missouri Cancer Associates Rrl

1705 E Broadway Ste 100, 
Columbia, MO 
 (5.4 miles away)
573-874-7800
Languages Spoken:
English
See accepted insurances

Umasankar Ramadoss is a Hematologist and an Oncologist in Columbia, Missouri. Dr. Ramadoss is highly rated in 87 conditions, according to our data. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Bone Marrow Aspiration, and Liver Embolization.

Mark Tungesvik
Expertise in
76
conditions
Dr. Mark Tungesvik
Oncology
Expertise in
76
conditions
Dr. Mark Tungesvik
Oncology

Missouri Cancer Associates Rrl

1705 E Broadway Ste 100, 
Columbia, MO 
 (5.4 miles away)
573-874-7800
Languages Spoken:
English
See accepted insurances

Mark Tungesvik is an Oncologist in Columbia, Missouri. Dr. Tungesvik is highly rated in 76 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Childhood Iron Deficiency Anemia, Bone Marrow Aspiration, and Endoscopy.

Liana Makarian
Expertise in
71
conditions
Dr. Liana Makarian
Oncology
Expertise in
71
conditions
Dr. Liana Makarian
Oncology

Missouri Cancer Associates Rrl

1705 E Broadway Ste 100, 
Columbia, MO 
 (5.4 miles away)
573-874-7800
Languages Spoken:
English
See accepted insurances

Liana Makarian is an Oncologist in Columbia, Missouri. Dr. Makarian is highly rated in 71 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Bone Marrow Aspiration, and Endoscopy.

Frequently Asked Questions about Dr. Donald Doll

How do I make an appointment with Dr. Donald Doll?

You can book an appointment with Dr. Donald Doll by calling their office at 573-882-8445. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Donald Doll a top-rated expert for Autoimmune Hemolytic Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Donald Doll is classified as an Distinguished expert for Autoimmune Hemolytic Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Donald Doll specialize in?

While Dr. Donald Doll is a Oncology, they have specific expertise in Autoimmune Hemolytic Anemia, Astrocytoma, and Posterior Fossa Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Donald Doll participate in research or clinical trials?

Yes. Dr. Donald Doll has published 22 articles and abstracts on conditions like Autoimmune Hemolytic Anemia. You can view a list of Dr. Donald Doll's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Donald Doll accept my insurance?

Dr. Donald Doll accepts most major insurance plans, including Humana and UnitedHealthcare. We recommend calling the office directly at 573-882-8445 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Doll's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 47 Advanced Conditions
    View All 100 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile